NCT04325568View on ClinicalTrials.gov

Developing Clinical Tools to Communicate Genetic Risk for Individuals Who Are Clinical High Risk for Psychosis

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 16, 2020

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2022

Conditions
Psychosis
Interventions
BEHAVIORAL

PsyGist and Clinician Manual

This is a pre-post test design aimed at conveying future genetic risk information to those at clinical high risk for psychosis. Participants will be assigned to either complete the Clinician Manual intervention (n= 27 participants) or PsyGist intervention (n=27 participants).

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

All Listed Sponsors
collaborator

New York State Psychiatric Institute

OTHER

lead

New York University

OTHER

NCT04325568 - Developing Clinical Tools to Communicate Genetic Risk for Individuals Who Are Clinical High Risk for Psychosis | Biotech Hunter | Biotech Hunter